Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial

Mutations in the epidermal growth factor receptor (EGFR) occur in approximately 20  % of North American patients with metastatic non-small cell lung cancer (NSCLC) [1]. The discovery of EGFR directed tyrosine kinase inhibitors (TKIs) has dramatically improved the outcomes of patients with EGFR mutant NSCLC [2,3]. Osimertinib is a third-generation EGFR TKI that was evaluated in F LAURA, a randomized phase three clinical trial against platinum-based chemotherapy. [4] A superior mOS of 39 months was observed.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research